Simon Sturge - 04 Oct 2024 Form 4 Insider Report for MoonLake Immunotherapeutics (MLTX)

Reporting relationship: Director
Issuer ticker: MLTX
Reported as of: 04 Oct 2024
Net transaction value: -$9,186,120
SEC form: 4
Accepted by SEC: 08 Oct 2024, 16:01:32 UTC
Prior SEC filing: 07 Jun 2024
Next SEC filing: 09 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Matthias Bodenstedt, Attorney-in-fact for Simon Sturge

Key filing fact

Simon Sturge filed Form 4 for MoonLake Immunotherapeutics (MLTX) on 08 Oct 2024.

Key facts

This page summarizes Simon Sturge's Form 4 filing for MoonLake Immunotherapeutics (MLTX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 08 Oct 2024, 16:01.

Change

Previous filing in this sequence was filed on 07 Jun 2024.
Current net transaction value: -$9,186,120.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MLTX transaction

Class A ordinary shares, par value $0.0001 per share

Sale

Transaction value: $9,186,120
Shares: -171,000
Change %: -50%
Price: $53.72
Shares after: 171,980
Date: 04 Oct 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $53.00 to $55.34. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.